

ARCH BIOPARTNERS INC.

Re: Material Change Report Form 51-102F3

1. Name and Address of Company:

Arch Biopartners Inc., (the “Company”)

545 King Street West
Toronto, Ontario
M5V 1M1

Mailing:

27 St. Clair Ave East
P.O. Box 305
Toronto, Ontario
M4T 2M5

2. Date of Material Change:

June 26, 2018

3. News Release:

A news release was distributed via NASDAQ (West Communications) in Toronto on June 26, 2018. A copy of the News release is attached as Schedule “A”.

4. Summary of Material Change

The Company issued common shares as a result of the exercise of common share warrants.

5. Full Description of Material Change

The Company received net proceeds of CAD \$332,750 during the current quarter from the exercise of 665,500 warrants with an exercise price of \$0.50 per common share.

All of the warrants were held by arm’s length parties and none were exercised by insiders of the Company. No commissions or fees were paid in connection to the exercise of the warrants. The proceeds will be used for general operations and the ongoing preparation of a pre-Investigational New Drug application for Metablok, the Company’s novel drug candidate to prevent acute kidney injury during cardiac surgery.

There is no material fact or material change about the Company that has not been generally disclosed.

Management of the Company believes the material changes described herein will have a positive impact on the Company's cash position, business operations and prospects for future corporate activity.

6. Reliance on subsection 7.1(2) or (3) of NI51-102

Not applicable.

7. Omitted Information

No information has been omitted from this report on the basis that it is confidential information.

8. Executive Officer

For further information regarding this report, please contact Richard Muruvé, a Director and CEO of the Company, at 647-428-7031.

The foregoing accurately discloses the material changes referred to herein.

DATED at Toronto, this 4th day of July 2018.

SCHEDULE A

PRESS RELEASE FOR IMMEDIATE DISTRIBUTION JUNE 26, 2018

ARCH BIOPARTNERS RECEIVES \$332,750 FROM THE EXERCISE OF WARRANTS

Toronto, Canada - Arch Biopartners, Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF) a portfolio-based biotechnology company, today announced that it received net proceeds of \$332,750 during the current quarter from the exercise of 665,500 warrants with an exercise price of \$0.50 per common share.

All of the warrants were held by arm's length parties and none were exercised by insiders of the Company. No commissions or fees were paid in connection to the exercise of the warrants. The proceeds will be used for general operations and the ongoing preparation of a pre-Investigational New Drug application for Metablok, the Company's novel drug candidate to prevent acute kidney injury during cardiac surgery.

About Arch Biopartners

Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch has established a diverse portfolio that includes Metablok (LSALT peptide), a potential treatment for inflammation, sepsis and cancer metastasis; AB569, a potential new treatment for antibiotic resistant bacterial infections in the lung, urinary tract or wounds; and, 'Borg' peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.

For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com

The Company has 58,457,929 common shares outstanding.

For more information, please contact:

Richard Muruve
Chief Executive Officer
Arch Biopartners, Inc.
647-428-7031
info@archbiopartners.com

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements

regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.